DESCICLOVIR PERMEATION OF THE HUMAN ERYTHROCYTE-MEMBRANE BY NONFACILITATED DIFFUSION

The mechanism of transport of desciclovir (DCV) - a structural analogue and prodrug of acyclovir (ACV) which provides an improved oral bioavailability of ACV - was investigated in human erythrocytes with a "papaverine-stop" assay. DCV influx was nonconcentrative, linearly dependent on DCV concentration (0.9-mu-M to 15 mM), insensitive (less-than-or-equal-to 20% inhibition) to nucleobases, nucleosides, or potent inhibitors of nucleoside transport, and occurred without permeant metabolism. However, DCV was a weak competitive inhibitor of the influx of adenine (K(i) = 1.3 mM) and of 5-iodo-2'-deoxyuridine (K(i) = 2.9 mM), permeants of the erythrocyte nucleobase and nucleoside carriers, respectively. This indicates that DCV has an affinity for both of these transporters, even though it appears not to be an effective permeant. We conclude that, in contrast to ACV which enters human erythrocytes primarily via the nucleobase carrier, DCV permeates these cells chiefly (greater-than-or-equal-to 80%) by nonfacilitated diffusion. This mechanistic difference in transport between ACV and DCV is attributed to differences in their desolvation energies and suggests an explanation for the differences in the oral bioavailability of ACV which is observed after the administration of these two "acyclic nucleosides."